Fri, December 22, 2023
[ 12:00 AM ] - WOPRAI
Wed, November 8, 2023
[ 12:00 AM ] - WOPRAI
Tue, July 18, 2023
[ 12:00 AM ] - WOPRAI
Tue, March 7, 2023
[ 12:00 AM ] - WOPRAI
Fri, February 17, 2023
[ 12:00 AM ] - WOPRAI
Thu, November 10, 2022
[ 12:00 AM ] - WOPRAI
Thu, October 13, 2022
[ 12:00 AM ] - WOPRAI
Tue, September 20, 2022
[ 12:00 AM ] - WOPRAI
Mon, August 29, 2022
[ 12:00 AM ] - WOPRAI
Wed, August 10, 2022
Wed, August 3, 2022
[ 12:00 AM ] - WOPRAI
Tue, August 2, 2022
Mon, June 6, 2022
Fri, June 3, 2022
Thu, May 5, 2022
[ 12:00 AM ] - WOPRAI
Tue, November 16, 2021
Wed, November 10, 2021
[ 12:00 AM ] - WOPRAI
Fri, October 8, 2021
[ 12:00 AM ] - WOPRAI
Fri, September 24, 2021
Thu, September 23, 2021
Tue, July 13, 2021
[ 12:00 AM ] - WOPRAI
Tue, June 29, 2021
[ 12:00 AM ] - WOPRAI
Wed, February 24, 2021
Tue, November 10, 2020
[ 12:00 AM ] - WOPRAI
Mon, October 26, 2020
Fri, October 16, 2020
[ 12:00 AM ] - WOPRAI
Tue, September 22, 2020
[ 12:00 AM ] - WOPRAI
Tue, July 28, 2020
Mon, June 1, 2020
Dane Leone Maintained (BPMC) at Strong Buy with Increased Target to $100 on, Dec 22nd, 2023
Dane Leone of Raymond James, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $85 to $100 on, Dec 22nd, 2023.
Dane has made no other calls on BPMC in the last 4 months.
There are 6 other peers that have a rating on BPMC. Out of the 6 peers that are also analyzing BPMC, 2 agree with Dane's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Michael Ulz of "Morgan Stanley" Maintained at Hold with Increased Target to $63 on, Friday, October 27th, 2023
- Peter Lawson of "Barclays" Maintained at Hold with Increased Target to $58 on, Friday, October 27th, 2023
These are the ratings of the 4 analyists that currently disagree with Dane
- Derek Archila of "Wells Fargo" Maintained at Buy with Increased Target to $115 on, Tuesday, December 19th, 2023
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $85 on, Monday, December 11th, 2023
- Ami Fadia of "Needham" Maintained at Strong Buy with Increased Target to $74 on, Friday, October 27th, 2023
- Matthew Biegler of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $85 on, Friday, October 27th, 2023
Contributing Sources